Portland-based biotech company Araceli Biosciences raised $11.2 million in new funding to fuel the expansion of its high-content imaging technology and AI-powered analysis used to speed drug discovery.
Araceli’s flagship platform is the Endeavor high content imaging system, which is designed for ultra high-throughput imaging — a process that measures the effects of chemical or genetic changes on cellular phenotypes.
The imaging is used to gather data that provides a more thorough understanding of cellular responses to potential drug candidates.
According to Araceli, traditional imaging systems lack speed and scalability, and Endeavor delivers results up to 40 times faster across a broad range of cellular assays. The company also says its AI-driven analysis software, called Clairvoyance streamlines workflows, reduces experimental errors, and speeds up drug discovery timelines.
“The future of AI-driven drug discovery and personalized medicine depends on imaging and analysis that happens in real time,” Matt Beaudet, CEO of Araceli Biosciences, said in a news release. “Minutes and seconds matter. The old model of waiting hours — or even days — for data is over. At Araceli, we’re building a platform that moves at the speed of science.”
